Market's view on Cambr Nutri Sci
Published on April 2024
- The company recently reported exceptional financial numbers, advising shareholders to retain their shares as it continues to grow shareholder value.
- Some stock watchers describe the company as a scam.
- Stock is considered undervalued following a positive update, with predictions of market capitalisation reaching £20m+, doubling the current levels.
- Difficulty in purchasing stock suggests a strong demand, with a limited free float contributing to a potentially low supply.
- Stock is speculated to rise sharply once large institutional investors have acquired significant holdings.
- The current level of support for the stock price around 3.9p is strong, with predictions of a swift increase to 4p and potentially up to 6p if the barrier is broken.
- Concerns are raised about a possible undervalued acquisition of the company, with suggestions that the stock is significantly undervalued compared to its actual worth.
- Frustration expressed towards the company’s broker, Cavendish, for not setting a target price, despite being bullish about the company’s prospects.
- Speculation exists that the company may become a takeover target due to its low market capitalisation in relation to its financial metrics.
- Positive trading updates have led to a strengthened stock book, with high demand causing a premium on large share purchases.
- The legal stance of the company regarding a £2 million government loan repayment is strong, with potential for counterclaims.
- Recent trading statement significantly surpassed expectations, enhancing investor confidence and contributing to a bullish outlook for the stock.